These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19925497)

  • 1. Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis.
    Wo JM; Eversmann J; Mann S
    Aliment Pharmacol Ther; 2010 Feb; 31(4):516-22. PubMed ID: 19925497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
    Howden CW
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():25-30. PubMed ID: 16303034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
    Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
    J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
    Andersson T; Hassall E; Lundborg P; Shepherd R; Radke M; Marcon M; Dalväg A; Martin S; Behrens R; Koletzko S; Becker M; Drouin E; Göthberg G
    Am J Gastroenterol; 2000 Nov; 95(11):3101-6. PubMed ID: 11095324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
    Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
    Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring.
    Bishop J; Furman M; Thomson M
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):50-5. PubMed ID: 17592364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma and gastro-oesophageal reflux: can the response to anti-reflux therapy be predicted?
    Kiljander T; Salomaa ER; Hietanen E; Helenius H; Liippo K; Terho EO
    Respir Med; 2001 May; 95(5):387-92. PubMed ID: 11392580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers.
    Phillips JO; Olsen KM; Rebuck JA; Rangnekar NJ; Miedema BW; Metzler MH
    Am J Gastroenterol; 2001 Feb; 96(2):367-72. PubMed ID: 11232677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J; Fullerton H; Briseno M; Cui H; Fass R
    Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of omeprazole treatment in gastro-oesophageal reflux disease.
    Hendel J; Hendel L; Hage E; Hendel J; Aggestrup S; Nielsen OH
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):417-20. PubMed ID: 8804867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
    Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
    Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.
    Størdal K; Johannesdottir GB; Bentsen BS; Knudsen PK; Carlsen KC; Closs O; Handeland M; Holm HK; Sandvik L
    Arch Dis Child; 2005 Sep; 90(9):956-60. PubMed ID: 16113133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
    Miner PB; Allgood LD; Grender JM
    Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.
    Leite LP; Johnston BT; Just RJ; Castell DO
    Am J Gastroenterol; 1996 Aug; 91(8):1527-31. PubMed ID: 8759655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study.
    Wo JM; Grist WJ; Gussack G; Delgaudio JM; Waring JP
    Am J Gastroenterol; 1997 Dec; 92(12):2160-5. PubMed ID: 9399745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
    Lundell L; Havu N; Miettinen P; Myrvold HE; Wallin L; Julkunen R; Levander K; Hatlebakk JG; Liedman B; Lamm M; Malm A; Walan A;
    Aliment Pharmacol Ther; 2006 Mar; 23(5):639-47. PubMed ID: 16480403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.